EP3007720A4 - Zusammensetzungen mit einem gc-makrophagen-aktivierenden faktor und verwendungen davon - Google Patents
Zusammensetzungen mit einem gc-makrophagen-aktivierenden faktor und verwendungen davonInfo
- Publication number
- EP3007720A4 EP3007720A4 EP14810595.0A EP14810595A EP3007720A4 EP 3007720 A4 EP3007720 A4 EP 3007720A4 EP 14810595 A EP14810595 A EP 14810595A EP 3007720 A4 EP3007720 A4 EP 3007720A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- compositions
- activating factor
- macrophage activating
- macrophage
- factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361832867P | 2013-06-09 | 2013-06-09 | |
PCT/IL2014/050516 WO2014199373A1 (en) | 2013-06-09 | 2014-06-09 | Compositions comprising gc- macrophage activating factor and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3007720A1 EP3007720A1 (de) | 2016-04-20 |
EP3007720A4 true EP3007720A4 (de) | 2016-12-07 |
Family
ID=52021738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14810595.0A Withdrawn EP3007720A4 (de) | 2013-06-09 | 2014-06-09 | Zusammensetzungen mit einem gc-makrophagen-aktivierenden faktor und verwendungen davon |
Country Status (7)
Country | Link |
---|---|
US (1) | US20160120946A1 (de) |
EP (1) | EP3007720A4 (de) |
JP (1) | JP2016520646A (de) |
CN (1) | CN105530950A (de) |
AU (1) | AU2014279627A1 (de) |
CA (1) | CA2913115A1 (de) |
WO (1) | WO2014199373A1 (de) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180078613A1 (en) * | 2015-04-07 | 2018-03-22 | Efranat Ltd. | Macrophage activating factor for treating benign or precancerous papillomas |
WO2016162867A1 (en) * | 2015-04-08 | 2016-10-13 | Efranat Ltd. | Combination therapy of macrophage activating factor and pd-1 signaling inhibitors |
JP6555738B2 (ja) * | 2015-05-20 | 2019-08-07 | 再生ファーマ株式会社 | 疲労を伴う疾患の予防改善剤 |
TW201722984A (zh) * | 2015-11-05 | 2017-07-01 | Glatt Ingtech Gmbh | 用於生產含GcMAF配方之乾燥劑型之方法及裝置 |
US20210198307A1 (en) * | 2017-12-15 | 2021-07-01 | Foundation For Biomedical Research And Innovation At Kobe | Method for producing active gcmaf |
AT521556A1 (de) * | 2018-07-24 | 2020-02-15 | Hg Pharma Gmbh | Vitamin D bindendes Protein |
RU2717218C1 (ru) * | 2019-08-07 | 2020-03-18 | Зайцева Инга Николаевна | Способ торможения роста подкожного трансплантата экспериментальной глиобластомы человека u-87, перевитого иммунодефицитным мышам nu/j |
CN112618482A (zh) * | 2019-09-24 | 2021-04-09 | 江苏恒瑞医药股份有限公司 | 新型蛋白制剂 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5712104A (en) * | 1995-06-07 | 1998-01-27 | Yamamoto; Nobuto | Diagnostic and prognostic elisa assays of serum or plasma α-N-acetylgalactosaminidase for cancer |
WO2004060396A2 (en) * | 2002-12-27 | 2004-07-22 | Chiron Corporation | Immunogenic compositions containing phospholpid |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1234383A (en) * | 1982-03-17 | 1983-09-22 | Inter-Yeda Ltd. | Interferon stabilised with polyvinyl-pyrrolidone |
DE3603444A1 (de) * | 1986-02-05 | 1987-08-06 | Thomae Gmbh Dr K | Pharmazeutische zubereitungsformen zur stabilisierung von interferon alpha |
US5177002A (en) * | 1989-11-20 | 1993-01-05 | Nobuto Yamamoto | In vitro enzymatic conversion of glycosylated human vitamin D binding protein to a potent macrophage activating factor |
US5177001A (en) * | 1989-11-20 | 1993-01-05 | Nobuto Yamamoto | In vitro enzymatic conversion of glycosylated mammalian vitamin D-binding protein to a potent macrophage activating factor |
US6806355B2 (en) * | 2001-08-14 | 2004-10-19 | Statens Serum Institut | Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc.globulin and a Gc-globulin medicinal product |
DE60237841D1 (de) * | 2001-11-13 | 2010-11-11 | Genentech Inc | Zusammensetzungen basierend auf APO2-Ligand/ TRAIL und ihre Verwendung |
SI21257A (sl) * | 2002-07-17 | 2004-02-29 | LEK farmacevtska dru�ba d.d. | Stabilni farmacevtski pripravek, ki vsebuje eritropoietin |
US8367054B2 (en) * | 2006-11-24 | 2013-02-05 | Cadila Healthcare Limited | Formulations of PEG-interferon alpha conjugates |
WO2012137199A1 (en) * | 2011-04-07 | 2012-10-11 | Efranat Ltd. | Macrophage activating factor for pharmaceutical compositions |
EP2561879A1 (de) * | 2011-08-23 | 2013-02-27 | Protea Biopharma N.V. | Makrophagenaktivierungsfaktor zur Verwendung bei der Behandlung des chronischen Ermüdungssyndroms sowie Erkrankungen und Störungen im Zusammenhang mit dem chronischen Ermüdungssyndrom |
-
2014
- 2014-06-09 CN CN201480032752.4A patent/CN105530950A/zh active Pending
- 2014-06-09 CA CA2913115A patent/CA2913115A1/en not_active Abandoned
- 2014-06-09 WO PCT/IL2014/050516 patent/WO2014199373A1/en active Application Filing
- 2014-06-09 JP JP2016517743A patent/JP2016520646A/ja active Pending
- 2014-06-09 US US14/893,354 patent/US20160120946A1/en not_active Abandoned
- 2014-06-09 AU AU2014279627A patent/AU2014279627A1/en not_active Abandoned
- 2014-06-09 EP EP14810595.0A patent/EP3007720A4/de not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5712104A (en) * | 1995-06-07 | 1998-01-27 | Yamamoto; Nobuto | Diagnostic and prognostic elisa assays of serum or plasma α-N-acetylgalactosaminidase for cancer |
WO2004060396A2 (en) * | 2002-12-27 | 2004-07-22 | Chiron Corporation | Immunogenic compositions containing phospholpid |
Non-Patent Citations (2)
Title |
---|
NOBUTO YAMAMOTO ET AL: "Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF", TRANSLATIONAL ONCOLOGY, NEOPLASIA PRESS, UNITED STATES, vol. 1, no. 2, 1 June 2008 (2008-06-01), pages 65 - 72, XP008154499, ISSN: 1944-7124, DOI: 10.1593/TLO.08106 * |
See also references of WO2014199373A1 * |
Also Published As
Publication number | Publication date |
---|---|
JP2016520646A (ja) | 2016-07-14 |
WO2014199373A1 (en) | 2014-12-18 |
US20160120946A1 (en) | 2016-05-05 |
EP3007720A1 (de) | 2016-04-20 |
CN105530950A (zh) | 2016-04-27 |
CA2913115A1 (en) | 2014-12-18 |
AU2014279627A1 (en) | 2015-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL273205A (en) | Preparations and methods | |
HK1223975A1 (zh) | 含納米氣泡的組合物及其用途 | |
HK1218837A1 (zh) | 組合物和方法 | |
HK1218560A1 (zh) | 組成與方法 | |
IL244850B (en) | Stabilized epinaconazole preparations, and their uses | |
GB2527241B (en) | Compositions and methods | |
ZA201602510B (en) | Strigolactone formulations and uses thereof | |
GB201317286D0 (en) | Composition and Use | |
GB201308072D0 (en) | Compositions and methods | |
EP2968474A4 (de) | Hautzusammensetzungen und verwendung | |
HK1220920A1 (zh) | 治療性組合物和其用途 | |
GB201321693D0 (en) | Composition and uses thereof | |
EP2968107A4 (de) | Kosmetikzusammensetzungen und verwendungen davon | |
IL276126B (en) | Preparations containing l-4-chloroquinonerine and their uses | |
EP3007720A4 (de) | Zusammensetzungen mit einem gc-makrophagen-aktivierenden faktor und verwendungen davon | |
GB201305813D0 (en) | Compositions and methods | |
EP2964610A4 (de) | Vinylsulfonbasierte 18f-labeling-zusammensetzungen sowie verfahren und verwendungen davon | |
HK1219691A1 (zh) | 醫藥組成物及其用途 | |
GB201313702D0 (en) | Fungicidal compositions and their use | |
GB201301979D0 (en) | New composition and use thereof | |
ZA201601880B (en) | Hetero-transglycosylase and uses thereof | |
IL246134A0 (en) | Gel preparations containing testosterone and their uses | |
GB201308242D0 (en) | Compositions and uses thereof | |
GB201301022D0 (en) | Composition and uses thereof | |
GB201322467D0 (en) | Composition and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20151116 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20161109 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 47/30 20060101ALI20161103BHEP Ipc: A61K 47/08 20060101ALI20161103BHEP Ipc: A61K 38/19 20060101AFI20161103BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20190103 |